Form 4: Director David Feinberg Receives Edwards Lifesciences RSU

Director David T. Feinberg was granted 3,251 restricted stock units under the Edwards Lifesciences 2020 Nonemployee Directors Stock Incentive Program.

Summary

• Director David T. Feinberg acquired 3,251 restricted stock units (RSUs) on May 8, 2026.
• The grant was issued under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• The RSUs are scheduled to vest fully on the earlier of one year from the grant date or the date of the next annual meeting of stockholders.
• Following this transaction, the director's total beneficial ownership of common stock is 9,087 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a non-employee director.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

The RSUs are subject to a one-year vesting schedule or will vest upon the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for directors at large-cap medical technology firms like Medtronic or Boston Scientific.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director incentive alignment.

Next Steps

• Vesting of the 3,251 restricted stock units in May 2027 or at the next annual meeting.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Director Compensation, Insider Ownership, Restricted Stock Units